3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Colorectal Neoplasms
58
Colonic Neoplasms
24
Rectal Neoplasms
22
Neoplasms
19
Pancreatic Neoplasms
18
Neoplasm Metastasis
17
Esophageal Neoplasms
9
Stomach Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
6
Small Cell Lung Carcinoma
5
Lung Neoplasms
5
Glioma
5
Glioblastoma
5
Brain Neoplasms
5
Neuroblastoma
4
Gliosarcoma
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma, Renal Cell
4
Melanoma
3
Intestinal Neoplasms
3
Gastrointestinal Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Sarcoma, Ewing
2
Recurrence
2
Rectal Diseases
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Interventions
Carboplatin
4
Sunitinib
3
Rituximab
3
Pemetrexed
3
ponatinib
2
pembrolizumab
2
osimertinib
2
Vincristine
2
Prednisone
2
Gemcitabine
2
Etoposide
2
Doxorubicin
2
Cyclophosphamide
2
ricolinostat
1
pralsetinib
1
pomalidomide
1
nilotinib
1
linifanib
1
ibritumomab tiuxetan
1
emvododstat
1
atezolizumab
1
Temozolomide
1
Taxes
1
Sorafenib
1
Papanicolaou Test
1
Paclitaxel
1
Melphalan
1
Irinotecan
1
Interleukin-2
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms by Histologic Type
×
Irinotecan
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts